Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Track all the latest updates and news of Par Drugs IPO.
March 24, 2023 2:07:00 PM
Par Drugs & Chemicals Ltd share price was up by -1.49% from the previous closing price of ?271.65. Who are peers of Par Drugs & Chemicals Ltd? The peers of Par Drugs & Chemicals Ltd are Sun ...
Published by : Business TodayApril 16, 2024 3:30:00 AM
UK biotech Compass Pathways is planning a $100 million US IPO as it seeks to further develop ... Compass laid out its plans to develop the drug known as COMP360, which is a crystalline formulation ...
Published by : pharmaphorumSeptember 30, 2023 4:13:00 PM
Carmot Therapeutics, which is developing drugs for diabetes and weight-loss, is reportedly mulling an IPO or possible sale to a large pharmaceutical company at a valuation of at least $1B.
Published by : MSNApril 4, 2024 3:30:00 AM
By this time last year, only four drug startups had gone public, raising $375 million. In 2022, nine companies had pulled in $744 million. The IPO activity has been accompanied by a step-up in ...
Published by : Yahoo FinanceMarch 29, 2024 3:30:00 AM
An IPO could happen as early as late July as the company looks to cash in on investor excitement about the next generation of weight-loss drugs and a revival in the biotech IPO market. A total of ...
Published by : The Financial TimesMarch 28, 2024 4:45:00 PM
The company has developed a diagnostic to identify patients amenable to treatment with an ecDNA-directed drug. In the IPO filing, the company said it is working with an in vitro diagnostic company ...
Published by : MedCity NewsMarch 18, 2024 3:30:00 AM
Contineum Therapeutics has become the latest biotech to file for an initial public offering (IPO) in the US, hoping to raise $150 million for its early clinical-stage candidate for progressive ...
Published by : pharmaphorumSeptember 15, 2023 11:24:00 PM
19 as the most likely date it will price its IPO, according to Wall Street insiders. The company is looking to raise $660 million by selling shares of its common stock, according to an updated SEC ...
Published by : U.S. News & World ReportMarch 5, 2024 3:17:00 PM
IPO Stock Faces Competition Apogee is facing some competition in eczema treatment, however. It's going up against Eli Lilly's drug, lebrikizumab. Both drugs target IL-13, a critical cytokine in ...
Published by : MSNApril 5, 2024 3:30:00 AM
Par Drugs and Chemicals Limited is an India-based company engaged in manufacturing of active pharma ingredients (APIs) and fine chemicals for the domestic market as well as for exports to ...
Published by : MintFebruary 28, 2024 2:30:00 AM
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Published by : MorningstarThe allotment status of Par Drugs and Chemicals Limited IPO is now available online. The public issue of Par Drugs IPO was open on May 3, 2019 and closed for subscription on May 8, 2019. The equity shares of the company to be list at NSE SME.
The IPO Shares of Par Drugs and Chemicals Limited IPO are proposed to list on Thursday, May 16, 2019 at NSE SME. The public issue of Par Drugs IPO was opened on May 3, 2019 and closed for subscription on May 8, 2019. Par Drugs IPO Listing Date and Information:
Par Drugs and Chemicals Limited is entering in the capital market with an IPO of 1,700,000 Equity Shares of Rs 10 aggregating up to Rs 8.53 Crore. The price for the issue has been set at Rs 51 Per Equity Share.
Incorporated in 1999, Gujarat based Par Drugs and Chemicals Limited is engaged in the business of manufacturing and developing active pharma ingredients (API) for the Indian and international markets. APIs are used as the main ingredient in making tablets, capsules, and other finished dosages. The company also produces various antacid molecules which are in great demand in the market.
The issue opens on May 3, 2019 and closes for subscription on May 8, 2019. The equity shares of the company to be list at NSE SME.
The issue of Par Drugs and Chemicals Limited opens on May 3, 2019 and closes for subscription on May 8, 2019. The equity shares of the company to be list at NSE SME. The price for the issue has been set at Rs 51 Per Equity Share.
The Par Drugs IPO is proposed to open on May 3, 2019. The IPO application ends on May 8, 2019.
Retail investors can apply in the retail or non-institutional investor category from May 3, 2019 to May 8, 2019. The Par Drugs IPO can be applied online through Net Bank (ASBA method) or the stock broker (UPI method).
The Par Drugs IPO will open for subscription on May 3, 2019. The public issue will close on May 8, 2019.
Useful Articles
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
RHP
